EA202191134A1 - Способы лечения смешанными металлосодержащими соединениями - Google Patents

Способы лечения смешанными металлосодержащими соединениями

Info

Publication number
EA202191134A1
EA202191134A1 EA202191134A EA202191134A EA202191134A1 EA 202191134 A1 EA202191134 A1 EA 202191134A1 EA 202191134 A EA202191134 A EA 202191134A EA 202191134 A EA202191134 A EA 202191134A EA 202191134 A1 EA202191134 A1 EA 202191134A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mixed metal
treatment
methods
containing compounds
treating
Prior art date
Application number
EA202191134A
Other languages
English (en)
Inventor
П. Мартин Петкович
Original Assignee
Эйрджен Фарма Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйрджен Фарма Лтд. filed Critical Эйрджен Фарма Лтд.
Publication of EA202191134A1 publication Critical patent/EA202191134A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Способ лечения и/или предотвращения сосудистой кальцификации может включать введение смешанного металлосодержащего соединения нуждающемуся в этом субъекту.
EA202191134A 2018-10-25 2019-10-25 Способы лечения смешанными металлосодержащими соединениями EA202191134A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862750791P 2018-10-25 2018-10-25
PCT/IB2019/001149 WO2020084349A1 (en) 2018-10-25 2019-10-25 Methods of treatment with mixed metal compounds

Publications (1)

Publication Number Publication Date
EA202191134A1 true EA202191134A1 (ru) 2021-07-13

Family

ID=68732014

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191134A EA202191134A1 (ru) 2018-10-25 2019-10-25 Способы лечения смешанными металлосодержащими соединениями

Country Status (12)

Country Link
US (1) US20200129545A1 (ru)
EP (1) EP3873490A1 (ru)
JP (1) JP2022509447A (ru)
KR (1) KR20210091185A (ru)
CN (1) CN113164515A (ru)
AU (1) AU2019363816A1 (ru)
BR (1) BR112021007757A2 (ru)
CA (1) CA3116635A1 (ru)
EA (1) EA202191134A1 (ru)
IL (1) IL282293A (ru)
MX (1) MX2020011742A (ru)
WO (1) WO2020084349A1 (ru)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20040226620A1 (en) 2002-09-26 2004-11-18 Daniel Therriault Microcapillary networks
US7664834B2 (en) 2004-07-09 2010-02-16 Maxsp Corporation Distributed operating system management
GB0502787D0 (en) 2005-02-10 2005-03-16 Ineos Silicas Ltd Pharmaceuticlly active compounds, their manufacture, compositions containing them and their use
US20060276534A1 (en) * 2005-03-17 2006-12-07 Amgen Inc. Methods of decreasing calcification
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) * 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) * 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
BR112015025805A2 (pt) * 2013-04-12 2017-07-25 Ardelyx Inc compostos de ligação de nh3 e métodos para inibir o transporte de fosfato

Also Published As

Publication number Publication date
CA3116635A1 (en) 2020-04-30
JP2022509447A (ja) 2022-01-20
WO2020084349A1 (en) 2020-04-30
KR20210091185A (ko) 2021-07-21
CN113164515A (zh) 2021-07-23
IL282293A (en) 2021-05-31
BR112021007757A2 (pt) 2021-07-27
MX2020011742A (es) 2021-02-15
US20200129545A1 (en) 2020-04-30
EP3873490A1 (en) 2021-09-08
AU2019363816A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2022010270A (es) Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion.
MX2020001406A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
MX2022008868A (es) Tratamiento del cancer con tg02.
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
MY201148A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
EA201891853A1 (ru) Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
EA201691647A1 (ru) Способы кратковременного и долгосрочного лечения зависимости от лекарственных средств
MX2018008299A (es) Metodos para administrar hepcidina.
EA201991650A1 (ru) Способы лечения неврологических расстройств
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
MA46459B1 (fr) Méthode de traitement de lésions rénales aiguës
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение